Table 1.

Clinical features of the affected individuals with MAGI2 mutations

Patient No.	Sex	Ethnicity	Familial/Sporadic	Age at Onset, mo	Consanguinity	Resistance to Steroids	First Native Biopsy	Second Native Biopsy	CKD Stage	Time to ESRF	Tx?	Disease Recurrence?	Extrarenal Phenotype	Treatment Used	Most Recent Serum Creatinine, μmol/L	Most Recent Albumin-to-Creatinine Ratio, mg/mmol	Length of Follow-Up, yr
180	M	W	Sporadic	3	No	Presumed	MCD (28 mo)	N/A	2	N/A	No	N/A	Pyloric stenosis, single–digit postaxial polydactyly, thrombocytosis	Enalapril, cyclosporin, tacrolimus, prednisolone, mycophenolate mofetil	32	83 (Serum albumin 17 g/L)	9.08
175	F	W	Familial	4	Yes	Presumed	Late Finnish–type CNS (22 mo)	End stage of Finnish-type CNS (26 mo)	Tx	1 yr, 9 mo	Yes	No	No	None	73	3.2	9.58
175S	F	W	Familial	1	Yes	Presumed	N/A	N/A	1	N/A	N/A	N/A	Mild peripheral branch pulmonary stenosis, patent foramen ovale	Captopril	24	2160 (Serum albumin 17 g/L)	2.33

ESRF, end stage renal failure; Tx, transplanted; M, boy; W, white; MCD, minimal change disease; N/A, not applicable; F, girl.